Free Newsletter
Military makes progress on dengue jab
Military scientists have been hard at work in Thailand developing a new vaccine to combat dengue fever. For the U.S. military, the prime motivation is protecting the troops from a disease that has afflicted American soldiers as recently as the ‘90s. But if they're successful in getting a new vaccine that can be commercialized by the middle of the next decade, they'll also save people from a disease that hospitalizes half a million a year.
"All we care about is that we get a vaccine that protects soldiers," Lt. Col. Stephen J. Thomas, a medical doctor who is director of dengue vaccine development in the Bangkok laboratory, told the New York Times, "Fortunately a lot of our concerns are also global health concerns."
And just down the street from the military's lab, Sanofi-Aventis and a local university are working on a separate vaccine that also has raised hopes of near-term vaccine.
"We're further along with the dengue vaccine than we've ever been," said Duane J. Gubler, director of the emerging infectious diseases department of the Duke-N.U.S. Graduate Medical School in Singapore. "There's a good possibility that we'll have a vaccine in five to seven years."
- read the article in the New York Times
ALSO: Vical said that that the Naval Medical Research Center plans to conduct preclinical and Phase I evaluation of a dengue DNA vaccine formulated with the company's Vaxfectin adjuvant and delivered with the Biojector 2000 needle-free injection system. Release
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




